Control of Cardiac Rate by “Funny” Channels in Health and Disease
... two decades pharmaceutical companies have been actively searching for pure heart-rate-modulating agents, drugs able to change heart chronotropism without altering other parameters that might negatively influence cardiovascular performance (e.g., cardiac inotropism). The concept of heart-rate reducti ...
... two decades pharmaceutical companies have been actively searching for pure heart-rate-modulating agents, drugs able to change heart chronotropism without altering other parameters that might negatively influence cardiovascular performance (e.g., cardiac inotropism). The concept of heart-rate reducti ...
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of
... Inpatient and outpatient males and females (≥18 years old) with heart failure (HF) [New York Heart Association (NYHA) functional class ...
... Inpatient and outpatient males and females (≥18 years old) with heart failure (HF) [New York Heart Association (NYHA) functional class ...
Supraventricular Tachycardia - Children`s Heart Federation
... the atria via an additional (abnormal) pathway. This creates a circular movement of electrical signals from atria to ventricles and back. This causes the heart to race quite suddenly for seconds, minutes or hours usually without any trigger. ...
... the atria via an additional (abnormal) pathway. This creates a circular movement of electrical signals from atria to ventricles and back. This causes the heart to race quite suddenly for seconds, minutes or hours usually without any trigger. ...
Implantable Cardioverter Defibrillator ICD Compliance
... Implantable Cardioverter Defibrillator (ICD) Compliance Checklist Coronary Artery Disease with Documented Prior MI and EF 35% EF 35%? ...
... Implantable Cardioverter Defibrillator (ICD) Compliance Checklist Coronary Artery Disease with Documented Prior MI and EF 35% EF 35%? ...
Long-term outcomes in high-risk patients with non-ST
... Several risk-scoring tools evaluated the risk of subsequent events in ACS patients, some of which can be used in NSTEMI patients (Table 2) [17–19, 27–30]. These risk scores, derived mainly from randomized controlled trials and registry data, assess a patient’s short- to medium-term risk of an advers ...
... Several risk-scoring tools evaluated the risk of subsequent events in ACS patients, some of which can be used in NSTEMI patients (Table 2) [17–19, 27–30]. These risk scores, derived mainly from randomized controlled trials and registry data, assess a patient’s short- to medium-term risk of an advers ...
wide qrs tachycardia
... Give Procainamide 10mg/kg IV bolus over 5 minutes If Ischemia related – Give Lidocaine If unsuccessful, Cardiovert Examine the ECG during VT and during sinus rhythm to determine the etiology of the arrhythmia ...
... Give Procainamide 10mg/kg IV bolus over 5 minutes If Ischemia related – Give Lidocaine If unsuccessful, Cardiovert Examine the ECG during VT and during sinus rhythm to determine the etiology of the arrhythmia ...
Idiopathic Ventricular Tachycardia: Transcatheter Ablation
... ablation within the coronary venous system.4 One also could consider to use an non-irrigated ablation catheter as a conventional one, when ablating within the cusps. If the mapping has been carried out systematically in the aortic root, few RF applications are sufficient to achieve the goal, otherwi ...
... ablation within the coronary venous system.4 One also could consider to use an non-irrigated ablation catheter as a conventional one, when ablating within the cusps. If the mapping has been carried out systematically in the aortic root, few RF applications are sufficient to achieve the goal, otherwi ...
Left Ventricular Non-Compaction: Mid-myocardial
... the non-compacted area [20,21], and decreased myocardial perfusion was reported in the non-compacted area [22-24]. Thus, defects in the coronary microcirculation might be responsible for ischemic lesions and myocardial fibrosis, despite no evidence of a previous myocardial infarction. In our study, ...
... the non-compacted area [20,21], and decreased myocardial perfusion was reported in the non-compacted area [22-24]. Thus, defects in the coronary microcirculation might be responsible for ischemic lesions and myocardial fibrosis, despite no evidence of a previous myocardial infarction. In our study, ...
Slide Set - Professional Heart Daily
... Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated ...
... Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated ...
AHA Scientific Statement: Drugs That May Cause or Exacerbate
... In the general population, patients with ≥5 chronic conditions have an average of 14 physician visits per year compared with only 1.5 for those with no chronic conditions.8–11 Medicare beneficiaries with HF see 15 to 23 different providers annually in both the inpatient and outpatient settings, whic ...
... In the general population, patients with ≥5 chronic conditions have an average of 14 physician visits per year compared with only 1.5 for those with no chronic conditions.8–11 Medicare beneficiaries with HF see 15 to 23 different providers annually in both the inpatient and outpatient settings, whic ...
School of Health Sciences - University of Nottingham
... 25% loss of output from the heart. However, the frequency of the non-conducted P waves will dictate symptoms. A loss of ventricular contraction every 10 beats is unlikely to cause any symptoms. A loss of output every 3 beats is more likely to cause symptoms as it represents a 33% loss of cardiac out ...
... 25% loss of output from the heart. However, the frequency of the non-conducted P waves will dictate symptoms. A loss of ventricular contraction every 10 beats is unlikely to cause any symptoms. A loss of output every 3 beats is more likely to cause symptoms as it represents a 33% loss of cardiac out ...
Seminars in Cardiothoracic and Vascular Anesthesia
... challenge. Anesthesia is associated with depression of sympathetic activity, on which many patients with diminished cardiac reserve rely. In addition to this indirect effect, anesthetics interfere with cardiovascular performance, either by a direct myocardial depression or by modifying cardiovascula ...
... challenge. Anesthesia is associated with depression of sympathetic activity, on which many patients with diminished cardiac reserve rely. In addition to this indirect effect, anesthetics interfere with cardiovascular performance, either by a direct myocardial depression or by modifying cardiovascula ...
Full PDF - Banglacardio :: Bangladesh Cardiac Society
... words. Number of tables/figures should be limited to 3. Include up to 10 most recent references. The patient’s ...
... words. Number of tables/figures should be limited to 3. Include up to 10 most recent references. The patient’s ...
October - Congenital Cardiology Today
... thrombus in the left main pulmonary artery. Initial echocardiogram findings reported a single tortuous PDA along with dextrocardia, an unbalanced AV canal defect with a dominant right ventricle and small left ventricle, and a large ostium primum ASD. There was also evidence of supracardiac total ano ...
... thrombus in the left main pulmonary artery. Initial echocardiogram findings reported a single tortuous PDA along with dextrocardia, an unbalanced AV canal defect with a dominant right ventricle and small left ventricle, and a large ostium primum ASD. There was also evidence of supracardiac total ano ...
Left Circumflex to Coronary Sinus Fistula
... of all cardiac anomalies. A CAF is defined as a direct connection between a coronary artery with right heart chambers including the right atrium, right ventricle, coronary sinus, superior vena cava, or pulmonary arteries. Although a single communication is most common, there are reports of multiple ...
... of all cardiac anomalies. A CAF is defined as a direct connection between a coronary artery with right heart chambers including the right atrium, right ventricle, coronary sinus, superior vena cava, or pulmonary arteries. Although a single communication is most common, there are reports of multiple ...
Cardiac Motion Analysis to Improve Pacing Site Selection in CRT1
... ejection fraction is maximized. Therefore, the improvement in cardiac performance is highly dependent on the pacing site that changes the sequence of ventricular activation in a manner that translates to an improvement in cardiac performance. As an important medical device, the pacemaker is used to ...
... ejection fraction is maximized. Therefore, the improvement in cardiac performance is highly dependent on the pacing site that changes the sequence of ventricular activation in a manner that translates to an improvement in cardiac performance. As an important medical device, the pacemaker is used to ...
Case Report Feminizing Adrenal Carcinoma Presenting with Heart
... The possible contribution of other adrenal hormones to our patient’s cardiomyopathy cannot be ruled out. It is possible that cortisol excess, as demonstrated by an abnormal result on 1 mg dexamethasone suppression testing, as well as a suppressed plasma ACTH level, was a factor in his cardiac presen ...
... The possible contribution of other adrenal hormones to our patient’s cardiomyopathy cannot be ruled out. It is possible that cortisol excess, as demonstrated by an abnormal result on 1 mg dexamethasone suppression testing, as well as a suppressed plasma ACTH level, was a factor in his cardiac presen ...
Drug-Induced QT Prolongation
... lengthened when there is an augmentation of inward depolarizing currents or inhibition of outward repolarizing potassium currents in ventricular myocytes.2 Most types of congenital LQTS are a result of genetic mutations in the ion channels active during the ‘plateau’ phase (phase 2) of the action po ...
... lengthened when there is an augmentation of inward depolarizing currents or inhibition of outward repolarizing potassium currents in ventricular myocytes.2 Most types of congenital LQTS are a result of genetic mutations in the ion channels active during the ‘plateau’ phase (phase 2) of the action po ...
Tina`s EKG Rhythm Recognition Notes
... EKG rhythm recognition Electrophysiology Two things that must be present: --Electrical activity—conductive cells --Mechanical activity—contracting cells Without electrical stimulus, mechanical activity doesn’t occur. The electrical activity of the heart is what is shown on the EKG, not mechanical ac ...
... EKG rhythm recognition Electrophysiology Two things that must be present: --Electrical activity—conductive cells --Mechanical activity—contracting cells Without electrical stimulus, mechanical activity doesn’t occur. The electrical activity of the heart is what is shown on the EKG, not mechanical ac ...
I IIa IIb III - Cardiosource
... Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated ...
... Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated ...
Pulmonary arterial hypertension: Monitoring the
... progression in PAH can be as short as several weeks to months. Indeed, in some clinical trials, patients with PAH randomized to receive placebo had significant declines in functional capacity, including several deaths in as little as 12 weeks.10 Therefore, most patients who require medical therapy f ...
... progression in PAH can be as short as several weeks to months. Indeed, in some clinical trials, patients with PAH randomized to receive placebo had significant declines in functional capacity, including several deaths in as little as 12 weeks.10 Therefore, most patients who require medical therapy f ...
pulmonary semilunar valves
... • damage to SA node - results in slower heart rate; artificial pacemakers usually installed surgically to correct rhythm • tachycardia - rapid heart rate (over 100 beats/min); may progress to fibrillation • bradycardia - slow heart rate (less than 60 beats/min); not ...
... • damage to SA node - results in slower heart rate; artificial pacemakers usually installed surgically to correct rhythm • tachycardia - rapid heart rate (over 100 beats/min); may progress to fibrillation • bradycardia - slow heart rate (less than 60 beats/min); not ...
A Pharmacokinetic and Pharmacodynamic Study of Intravenous
... laxis, an increasing heart rate, cardiac arrhythmias and increasing incidences of myocardial ischemia.3,4 Some of these side effects have also been observed with adenosine monophosphate-dependent inotropes (phosphodiesterase inhibitors) such as amrinone, milrinone, or enoximone.5 Due to lack of posi ...
... laxis, an increasing heart rate, cardiac arrhythmias and increasing incidences of myocardial ischemia.3,4 Some of these side effects have also been observed with adenosine monophosphate-dependent inotropes (phosphodiesterase inhibitors) such as amrinone, milrinone, or enoximone.5 Due to lack of posi ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.